SCHEMBL7175012

SCHEMBL7175012

Cc1cccc(C)c1C(=O)C(P=O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 4/20 0.46
CYP2D6 P10635 2/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
HTT P42858 1/20 0.37
TDP1 Q9NUW8 2/20 0.37
LMNA P02545 1/20 0.37
ACP3 P15309 1/20 0.37
SLC6A9 P48067 5/20 0.36
GPR52 Q9Y2T5 1/20 0.36
HSP90AA1 P07900 1/20 0.36
ATM Q13315 1/20 0.36
FABP3 P05413 1/20 0.35
FABP4 P15090 1/20 0.35
SRC P12931 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7189027 0.89 FABP3 (0.43) L3MBTL1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7189152 0.87 NPSR1 (0.37) L3MBTL1HTTTDP1LMNAACP3
SCHEMBL7183330 0.83 CYP1A2 (0.37) L3MBTL1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7177680 0.81 L3MBTL1 (0.36) L3MBTL1CYP2D6CYP1A2CYP3A4CYP2C9
SCHEMBL7189908 0.79 ALDH1A1 (0.42) L3MBTL1CYP2D6TDP1LMNAACP3
SCHEMBL7185486 0.79 CA12 (0.51) HTTTDP1LMNAFABP4
SCHEMBL6468660 0.76 L3MBTL1 (0.38) L3MBTL1HTTTDP1GPR52HSP90AA1
SCHEMBL7186879 0.76 L3MBTL1 (0.43) L3MBTL1CYP1A2CYP3A4CYP2C9CYP2C19
SCHEMBL7189505 0.75 L3MBTL1 (0.40) L3MBTL1CYP2D6CYP1A2CYP3A4CYP2C9
SCHEMBL7182262 0.74 L3MBTL1 (0.42) L3MBTL1CYP2D6CYP1A2CYP3A4CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 L3MBTL1 302/4885CYP2D6 1673/4885CYP1A2 1595/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 L3MBTL1 126/4885CYP2D6 2229/4885CYP1A2 2020/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.